What is Levamlodipine
Levamlodipine is an oral calcium channel blocker approved as monotherapy or in combination with other antihypertensive agents for the treatment of hypertension.
It is the S-isomer of amlodipine. Amlodipine is a 1:1 racemic mixture of levamlodipine and dextroamlodipine and levamlodipine has been identified as the pharmacologically active, antihypertensive isomer.
Levamlodipine has demonstrated equivalent antihypertensive efficacy at half the dose of amlodipine and may have a lower incidence of peripheral edema.
In a meta-analysis, the incidence of peripheral edema was significantly lower with levamlodipine when all included studies were considered, but no significant difference was found when the authors analyzed only the high-quality trials.
Another study compared the incidence of leg edema with levamlodipine to amlodipine as part of triple antihypertensive therapy in adult patients (30 to 64 years) with essential hypertension.
The authors concluded that levamlodipine at doses of 2.5 mg or 5 mg once daily provided equivalent blood pressure reduction when compared to amlodipine 5 mg or 10 mg once daily.
New edema occurred in 31.4% and 46.5% of levamlodipine and amlodipine patients, respectively (p=0.03; absolute risk reduction = 15.1%). In addition, amlodipine therapy was associated with significantly increased pitting edema scores and patient rated edema scores compared to levamlodipine therapy (p = 0.038 and p = 0,036, respectively).
There was no significant difference between levamlodipine and amlodipine in the incidence of edema resolution; 55% and 43.59%, respectively.
For the treatment of hypertension, either alone or in combination with other antihypertensive agents
- blood pressure
- acute myocardial infarction
- aortic stenosis
- coronary artery disease
- hepatic disease
Levamlodipine is contraindicated in patients with a known amlodipine hypersensitivity or levamlodipine hypersensitivity.
No information is available regarding drug interactions associated with Levamlodipine